Clinical pharmacist and diabetes educator Mary Taylor stresses the importance of access to various healthcare providers for patients, particularly those with diabetes. She points out that primary care teams should ideally include a diabetes care and education specialist, a dietitian, and a pharmacist to ensure comprehensive diabetes management. Furthermore, Taylor emphasizes the need for legislative interventions to demonstrate the benefits and cost-effectiveness of this integrated care model.
According to Taylor, the increasing use of semaglutide, a medication initially intended for diabetes but now also used for weight loss, has started to impact patient care. The demand for this drug has outpaced the supply, complicating diabetes management for some patients. She suggests that the medication’s manufacturers should strive to meet demand or enact stricter regulations regarding its use.
Insurance-related issues are another hurdle for patients seeking to access semaglutide, as the rules surrounding this medication can change based on varying factors. Taylor highlights the negative impact of these challenges on patients, whether they use the medication for weight management or diabetes treatment.
Turning to the use of diabetes medications in younger populations, Taylor notes that a number of such treatments have been officially cleared for paediatric use. However, there is limited long-term data to confirm if these medications can prevent complications like they do in adults.
Nonetheless, she underscores the urgent need for such medications in young patients, given the rising rates of obesity and type 2 diabetes. Given the chronic nature of obesity and its associated complications, Taylor recognizes the potential role of genetic factors. Therefore, she concludes, making these medications consistently available in pediatrics is crucial, albeit fraught with challenges.
